



Swansea University
Prifysgol Abertawe



Cronfa - Swansea University Open Access Repository

This is an author produced version of a paper published in :
Journal of Hypertension

Cronfa URL for this paper:
<http://cronfa.swan.ac.uk/Record/cronfa30984>

Paper:

Borghgi, C., Rodriguez-Artalejo, F., De Backer, G., Dallongeville, J., Medina, J., Guallar, E., Perk, J., Banegas, J., Tubach, F., Roy, C. & Halcox, J. (2016). The association between blood pressure and lipid levels in Europe. *Journal of Hypertension*, 34(11), 2155-2163.
<http://dx.doi.org/10.1097/HJH.0000000000001078>

This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions. When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO database to judge whether or not it is copyright safe to add this version of the paper to this repository.
<http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/>

The association between blood pressure and lipid levels in Europe:

EURIKA

Claudio BORGHI^a, Fernando RODRIGUEZ-ARTALEJO^{b,c}, Guy De BACKER^d,
Jean DALLONGEVILLE^e, Jesús MEDINA^f, Eliseo GUALLAR^g, Joep PERK^h, José
R BANEGAS^{b,c}, Florence TUBACH^{i,j,k}, Carine ROY^{i,j}, and Julian P HALCOX^l

The final definitive version of this paper has been published in the Journal of Hypertension, November 2016 by Lippincott, Williams & Wilkins All rights reserved.

doi: 10.1097/HJH.0000000000001078.

http://journals.lww.com/jhypertension/Abstract/2016/11000/The_association_between_blood_pressure_and_lipid.10.aspx

The association between blood pressure and lipid levels in Europe:

EURIKA

Running head: Blood pressure and lipid levels

Claudio BORGHI^a, Fernando RODRIGUEZ-ARTALEJO^{b,c}, Guy De BACKER^d,
Jean DALLONGEVILLE^e, Jesús MEDINA^f, Eliseo GUALLAR^g, Joep PERK^h, José
R BANEGAS^{b,c}, Florence TUBACH^{i,j,k}, Carine ROY^{i,j}, and Julian P HALCOX^l

^aDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy;

^bDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad

Autónoma de Madrid/IdiPaz, Madrid, Spain; ^cCIBER of Epidemiology and Public Health

(CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; ^dDepartment of Public Health,

Ghent University, Ghent, Belgium; ^eINSERM U 744, Institut Pasteur de Lille, Université

Lille-Nord de France, Lille, France; ^fMedical Evidence and Observational Research, Global

Medical Affairs, AstraZeneca Farmacéutica Spain, Madrid, Spain; ^gDepartments of

Epidemiology and Medicine and Welch Center for Prevention, Epidemiology and Clinical

Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA;

^hSchool of Health and Caring Sciences, Linnaeus University, Kalmar, Sweden; ⁱDépartement

d'Épidémiologie et Recherche Clinique, Assistance Publique – Hôpitaux de Paris, Hôpital

Bichat, Paris, France; ^jINSERM, CIC-EC 1425, ECEVE, UMR 1123, Paris, France and

Département d'Épidémiologie et Recherche Clinique, Centre de pharmacoépidémiologie

(Cephepi), Assistance Publique – Hôpitaux de Paris, Hôpital Bichat, Paris, France;

^kUniversité Paris Diderot, Sorbonne Paris Cité, ECEVE, UMR 1123, Paris, France; ^lSwansea

University School of Medicine, Swansea, UK

Funding

EURIKA was funded by AstraZeneca. The study was overseen by an independent academic steering committee. The authors had full access to all data and had final responsibility for the contents of the manuscript and the decision to submit it for publication.

Conflicts of interest

Claudio Borghi has received speaker and consulting fees from Menarini, Merck Sharp & Dohme, Servier and Takeda. Jean Dallongeville and Julian P Halcox have received speaker and consulting fees from AstraZeneca. Jesús Medina is an employee of AstraZeneca. Eliseo Guallar and Florence Tubach have received payment for statistical analysis work from AstraZeneca. For the remaining authors no competing interests are declared.

Corresponding author

Professor Claudio Borghi, Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Via Albertoni 15 – Pad. 2, 40138 Bologna, Italy. Tel: +39 0516362843; fax: +39 051391320; e-mail: claudio.borghi@unibo.it

Word count (including references): 4195

Word count (abstract): 245

Number of tables: 3

Number of figures: 2

Number of supplementary digital content files: 1 supplementary table

ABSTRACT

Objectives: Several studies have suggested a positive association between serum lipid levels and blood pressure (BP). This study investigated this association in a large population from 12 European countries.

Methods: Data were taken from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; ClinicalTrials.gov identifier: NCT00882336). Associations between BP and lipid levels in patients free from cardiovascular disease (CVD) and with at least one major CVD risk factor ($N = 7641$) were assessed using linear regression analyses.

Results: Overall, 72.8% and 64.8% of patients had hypertension and dyslipidaemia, respectively; 47.0% had both conditions. Regression coefficients (95% confidence interval [CI]) for the associations of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, total cholesterol and apolipoprotein B levels with systolic BP, adjusted for age, sex and body mass index, were 0.93 mmHg/mmol/L (0.54 to 1.31), 1.07 mmHg/mmol/L (0.73 to 1.40), 1.02 mmHg/mmol/L (0.69 to 1.35) and 4.94 mmHg/g/L (3.43 to 6.46), respectively. The corresponding values (95% CI) for the associations with diastolic BP were 0.96 mmHg/mmol/L (0.73 to 1.19), 0.95 mmHg/mmol/L (0.75 to 1.15), 0.87 mmHg/mmol/L (0.67 to 1.07) and 4.33 mmHg/g/L (3.42 to 5.23), respectively. Most of these associations remained significant whether patients were treated with statins or not.

Conclusions: Small but statistically significant associations between lipid levels and BP were observed in a large, multinational European population. Further research is warranted to assess the causality of this association and its implications on the management of patients with both hypertension and dyslipidaemia.

Keywords: blood pressure, cholesterol, dyslipidaemia, hypertension

Abbreviations

ACE, angiotensin-converting enzyme; apo-A1, apolipoprotein A1; apo-B, apolipoprotein B; AT1, angiotensin II type 1; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; DBP, diastolic blood pressure; EURIKA, European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol ; SBP, systolic blood pressure

INTRODUCTION

Dyslipidaemia and hypertension are two of the principal, established, modifiable risk factors for cardiovascular disease (CVD) and coexist in a substantial proportion of patients [1-3]. It has also been shown that the coronary heart disease (CHD) risk in patients with hypertension and dyslipidaemia is greater than the sum of CHD risks for hypertension and dyslipidaemia when they occur alone [4], thereby supporting a degree of clinical interaction between the two risk factors. Despite recent improvements in the understanding and treatment of cardiovascular risk factors [5-7], control of both serum lipid levels and blood pressure (BP) remains suboptimal [8-13].

As part of the recent European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; ClinicalTrials.gov identifier: NCT00882336), a study of the primary prevention of CVD in Europe, we have shown that only 41.2% of patients with no history of CVD and being treated for dyslipidaemia attained both total cholesterol and low-density lipoprotein cholesterol (LDL-C) targets of <5 and <3 mmol/L, respectively [8]. Similarly, only 38.8% of these patients being treated for hypertension achieved the BP target of <140/90 mmHg, as recommended by the most recent European guidelines [14]. The high proportion of patients unable to achieve satisfactory control of both serum lipid levels and hypertension suggests that there may be an interaction between the two risk factors. Indeed, several studies have shown that there may be a positive association between elevated serum lipid levels and hypertension [15,16] and that better lipid control may lead to a lower incidence of new-onset hypertension [17,18].

Statins are the mainstay of cholesterol-lowering drug therapy. Although the primary function of statins is to reduce cholesterol levels, it has been suggested that they may also have a mild, but clinically relevant, BP-lowering effect, particularly in patients with poorly controlled

hypertension [19-21]. Moreover, several pathophysiological mechanisms may account for the association between BP and serum lipid profile, including overexpression of angiotensin II type 1 (AT1) receptors and non-angiotensin-converting enzyme (non-ACE)-mediated upregulation of angiotensin II production as a result of elevated serum lipid levels [22-25].

Although several studies have reported an association between BP and serum lipid levels, most were published more than 10 years ago [15,26,27], included small numbers of individuals [16,18,27], were conducted in specific countries or cities [1,15,16,18,26,27], did not stratify the results according to statin treatment status [1,15,16,18,26] or were population based and did not focus on the clinical setting [1,15,16,18,27]. In order to provide a contemporary and comprehensive assessment of the association between BP and dyslipidaemia in usual clinical practice across several European countries in patients with varying degrees of CVD risk, we performed a secondary analysis of data from EURIKA.

METHODS

Study design and participants

EURIKA was conducted in 12 European countries (Austria, Belgium, France, Germany, Greece, Norway, Russia, Spain, Sweden, Switzerland, Turkey and the United Kingdom) [8]. Data collection started in May 2009 and ended in January 2010, with a 3-month data-collection period for each country. The study protocol was approved by the appropriate clinical research ethics committee in each participating country, and all patients provided signed informed consent. The methods for the study have been reported in detail elsewhere [28]. Briefly, the study recruited patients with at least one risk factor for CVD, but no history of cardiovascular events. The study sample was selected in a two-step process that involved recruitment of physicians and their patients [28,29]. In the first stage, a random sample of

primary care physicians and specialists involved in CVD prevention, stratified by age, sex and specialty, were selected for invitation to participate using the OneKey database (Cegedim Dendrite, Boulogne-Billancourt, France). The percentage of participating physicians among those invited was 7.9% [28]. In all countries, primary care physicians were the predominant type of physician, making up 64% of physicians overall [28]. In total, 809 physicians (approximately 60 per country) agreed to participate in EURIKA [29]. In the second stage, participating physicians sequentially invited patients who met the selection criteria (age 50 years or older, free of CVD but having at least one major cardiovascular risk factor [8]. The major cardiovascular risk factors were: dyslipidaemia; hypertension; smoking (current or former smoker, with >100 cigarettes smoked in lifetime); diabetes mellitus (fasting plasma glucose ≥ 7.0 mmol/L [126 mg/dL] or receiving antidiabetic medication [insulin or oral medications]); obesity (body mass index [BMI] ≥ 30 kg/m² or waist circumference ≥ 102 cm in men and ≥ 88 cm in women) [28]. Approximately 12,300 patients were invited to participate, of whom 7641 (about 600 patients per country) accepted [8].

Assessment of CVD risk factors

Demographic information and other details of participating patients were gathered from medical records and patient interviews. For each patient, a physical examination was conducted, BP was measured, and a 12-hour fasting blood sample was collected within 1 day of the initial outpatient consultation.

BP measurements were obtained under standardized conditions, using calibrated mercury sphygmomanometers or validated automated devices and appropriate-sized cuffs. The mean of three consecutive measurements in the sitting position and spaced 1–2 minutes apart was used for the analyses [14]. Blood sample analysis was performed by a central laboratory (BioAnalytical Research Corporation, Ghent, Belgium) for samples from all patients except

those in Russia (approximately 5% of all patients), for which laboratory analysis was conducted locally.

High-density lipoprotein cholesterol (HDL-C) concentration was measured by a modified enzymatic method and total cholesterol concentration by the glycerophosphate oxidase–peroxidase-4-aminophenazone (GPO–PAP) method (using the Roche Modular P Chemistry Analyzer [Roche Diagnostics, Indianapolis, IN, USA]). LDL-C concentration was calculated by the Friedewald formula [30]. Apolipoprotein A1 (apo-A1) and apolipoprotein B (apo-B) concentrations were measured using immunoturbidimetric methods.

Definition of blood pressure and serum lipid level status

BP status was defined as follows: normotensive (systolic BP [SBP] <120 mmHg and diastolic BP [DBP] <80 mmHg and not receiving antihypertensive medication); normal-to-high-normal BP (SBP 120 to <140 mmHg and DBP 80 to <90 mmHg and not receiving antihypertensive medication); hypertensive (SBP \geq 140 mmHg and/or DBP \geq 90 mmHg or being treated with one or more antihypertensive drugs) [31].

Patients were defined as having dyslipidaemia if they had a serum LDL-C concentration \geq 4.9 mmol/L (190 mg/dL), a serum HDL-C concentration <1.0 mmol/L (40 mg/dL) for men or <1.3 mmol/L (50 mg/dL) for women, a serum non-HDL-C concentration \geq 5.2 mmol/L (200 mg/dL) for men or \geq 4.9 mmol/L (190 mg/dL) for women, or if they were receiving lipid-lowering medication [32].

Statistical analyses

Statistical analyses were performed using SAS V9.2 (SAS Institute, Inc., Cary, NC, USA). Associations between BP (SBP, DBP and pulse pressure) and serum lipid levels were assessed using multivariate linear regression analyses. In a first model (model A), estimates

were adjusted for age, sex and BMI. Associations were also assessed with a model further adjusted for statin use, antihypertensive treatment (yes/no), number of cardiovascular risk factors (among smoking, diabetes and dyslipidaemia), physical activity and country (model B). Statistical significance was defined as two-sided $P < 0.05$. For analyses stratified by statin use, estimates were adjusted for model A variables plus antihypertensive treatment (yes/no), physical activity and country.

RESULTS

Patient demographics and general characteristics

The characteristics of the 7641 patients in the EURIKA study population are presented in Table 1. The mean age of subjects was 63.2 years, and there were more women (51.6%) than men (48.4%). The overall proportion of patients with hypertension was 72.8%, with a notable difference between countries (Supplementary Table 1). The countries with the highest and the lowest proportions of individuals with hypertension were Sweden (82.2%) and Austria (61.4%), respectively. Overall, 5239 patients (68.6%) were receiving antihypertensive medications, with the most common treatments being diuretics, angiotensin II antagonists and ACE inhibitors (Table 2).

The prevalence of dyslipidaemia was 64.8%, with a between-countries range of 57.5%–73.7%. Austria had the lowest proportion of patients with dyslipidaemia and Greece the highest. Patients with both hypertension and dyslipidaemia accounted for 47.0% of the study participants (between-countries range: 41.0%–58.4%). The mean serum concentrations of LDL-C, HDL-C, total cholesterol and apo-B were 3.2, 1.4 and 5.5 mmol/L and 0.9 g/L, respectively.

Relationship between blood pressure and serum lipid profile

In order to determine the relationship between BP (SBP and DBP) and serum lipid levels (LDL-C, HDL-C, non-HDL-C, total cholesterol, apo-A1 and apo-B), scatterplots with regression lines were created for all patients for whom data were available (Figures 1 and 2). When adjusted for age, sex and BMI, linear regression analyses (model A) showed that LDL-C, non-HDL-C, total cholesterol, apo-A1 and apo-B levels were significantly associated with SBP, and that LDL-C, non-HDL-C, total cholesterol and apo-B levels were significantly associated with DBP (Table 3). Similar results were observed when the regression analyses were further adjusted for use of statins, antihypertensive treatment, number of cardiovascular risk factors, physical activity and study country (model B).

When stratifying the analyses by statin use, the aforementioned associations, adjusted for age, sex, BMI, antihypertensive treatment, physical activity and study country, remained significant, and the associations between apo-A1 and DBP in patients not treated with a statin became significant (Table 4).

Relationship between pulse pressure and serum lipid profile

Scatterplots with regression lines were created to determine the relationship between pulse pressure (SBP minus DBP) and serum lipid levels (Figure 3). Linear regression analyses adjusted for model B showed that HDL-C, total cholesterol and apo-A1 were significantly associated with pulse pressure (Table 5). When stratifying the analyses by statin use, none of the aforementioned associations, adjusted for age, sex, BMI, antihypertensive treatment, physical activity and study country, remained significant when only patients treated with statins were considered. The associations between total cholesterol, apo-A1 and pulse pressure remained significant when only patients not treated with statins were considered (Table 5).

DISCUSSION

The present study has shown a small but statistically significant positive association between serum lipid levels (LDL-C, total cholesterol, non-HDL-C and apo-B) and BP in a large sample of patients with at least one risk factor for CVD but no history of CVD who were enrolled in a setting of day-to-day clinical practice. The relationship between BP and serum lipid profile involves both SBP and DBP, and is independent of statin use, antihypertensive treatment and number of cardiovascular risk factors. A similar association has been previously described in both the Tromsø Study [15] and the Brisighella Heart Study [16]. The Tromsø Study showed that non-HDL-C levels increased significantly with increasing SBP and DBP [15]. Similarly, in the Brisighella Heart Study, LDL-C and apo-B serum levels appeared to be significantly related to SBP and DBP [16]. For example, in a model adjusted for age, sex, BMI, smoking habit, physical activity level and serum creatinine, apo-B appeared to be significantly positively related to both SBP (unstandardized coefficient 0.166 mmHg/mg/dL; 95% confidence interval [CI] 0.133 to 0.198; $P < 0.001$) and DBP (unstandardized coefficient 0.071 mmHg/mg/dL; 95% CI 0.051 to 0.090; $P < 0.001$). Analogously, in EUROASPIRE III, a survey of patients previously hospitalized for coronary heart disease, a negative association was observed between dyslipidaemia and BP control in individuals using antihypertensive medication [33]. Our results are also in line with recent findings that higher LDL-C levels are associated with a higher incidence of new-onset hypertension [17,18]. These data support the hypothesis that dyslipidaemia may contribute significantly to the onset and progression of hypertension.

The association between serum lipid levels and BP is corroborated by the results of a recent meta-analysis of 40 prospective controlled studies involving a total of 45,113 patients, which showed a small reduction in mean SBP (2.62 mmHg; 95% CI 1.84 to 3.41; $P < 0.001$) and in

mean DBP (0.94 mmHg; 95% CI 0.57 to 1.31; $P < 0.001$) in patients treated with statins compared with those not treated with statins [19]. The positive effect of statins on BP was slightly greater in hypertensive patients than in normotensive patients. Furthermore, a recent study that included data from two separate interventional studies in hypertensive and diabetic individuals consistently showed that statin use was associated with lower BP and reduced aldosterone levels [21]. Lower aldosterone levels at higher statin doses indicated a dose–response effect for statin use [21]. Additionally, ex vivo experiments confirmed that statins blocked potassium-stimulated production of aldosterone, suggesting that statins act downstream from the AT1 receptor to decrease aldosterone production [21].

From a practical point of view, the BP changes associated with the modifications of serum lipid profile can have a measurable impact on cardiovascular risk profile [14]. A BP increase of a few mmHg in the general population has been associated with an increase in the risk of fatal and non-fatal coronary artery disease and stroke in both normotensive and hypertensive patients [34]. Conversely, a reduction in BP of the magnitude observed in patients under statin treatment may have a significant impact on the prevention of CVD at a population level. Results from an overview of observational studies and randomized trials suggest that a 2 mmHg reduction in DBP would result in a 17% decrease in the prevalence of hypertension as well as a 6% reduction in the risk of coronary heart disease and a 15% reduction in the risk of stroke and transient ischaemic attack [35]. These findings highlight the importance of improving lipid control in the general population, with the aim of reducing the burden of CVD attributable to elevated BP.

Several pathophysiological mechanisms have been suggested to explain the observed association between dyslipidaemia and hypertension. A potential explanation is that elevated LDL-C levels can progressively impair endothelial function and promote vascular stiffness,

thus leading to an increase in BP. Patients in EURIKA were free of overt CVD, and the possibility of a high prevalence of atherosclerotic disease in this population is unlikely. However, total cholesterol and apo-A1 were significantly associated with pulse pressure overall and in patients not treated with statins, although not in patients treated with statins. Alternatively, more complex mechanisms may explain the effect of dyslipidaemia on BP. In particular, several studies have suggested that high levels of LDL-C may increase instability of mRNA for AT1 receptors [22,36,37], leading to overexpression of AT1 receptors in vascular tissues. Activation of these receptors by angiotensin II results in an enhanced vasoconstrictive response that might contribute to the development of hypertension and atherosclerotic disease, an effect has also been described *in vivo* [38-40]. In addition, angiotensin II promotes the oxidation of LDL-C, with increased levels of oxidized LDL-C also contributing to overexpression of AT1 receptors [41]. Beyond direct effects of LDL-C on AT1 receptors, it has also been suggested that dyslipidaemia may increase the chymase-dependent production of angiotensin II [24,42]. This increase in ACE-independent production of angiotensin II may act synergistically with upregulation of AT1 receptors in hypercholesterolaemic patients, which would explain the observed correlation between serum lipid levels and BP.

Regardless of the mechanism involved, the evidence of a significant association between elevated LDL-C and BP highlights the importance of controlling serum lipid levels in the general population and in patients with hypertension in particular, who may benefit from a more intensive statin treatment regimen.

Strengths and limitations

Particular strengths of our study include a large sample of patients from multiple countries, the collection of data with standardized procedures and a reliable data set provided by the use

of a central laboratory for analyses of serum lipid levels. A limitation inherent in the observational study design is that the causal contributions of pathophysiological mechanisms are not elucidated. Furthermore, the cross-sectional design of the study does not allow the direction of the association between serum lipid levels and BP to be established. It should also be noted that in linear regression analyses, several parameters that may affect BP and/or serum lipid levels, such as dietary habits, were not taken into account. Also, although analyses were adjusted for antihypertensive treatment (yes/no) and for number of cardiovascular risk factors, they were not adjusted separately for class of antihypertensive treatment or type of cardiovascular risk factor, and relationships between BP and lipid levels were not assessed separately in hypertensive participants. Furthermore, information on medication adherence was not available and could thus not be taken into consideration. Although further research is required to determine whether there is a causal relationship between serum lipid levels and BP, our results suggest that dyslipidaemia should be carefully assessed and managed in patients with hypertension.

CONCLUSION

In this study, we have observed a significant association between serum lipid levels and BP in a large, multinational, European, primary CVD prevention population. Our results are in agreement with those of previously conducted studies [15,16]. Given the high concomitant prevalence of hyperlipidaemia and hypertension observed in this and other studies [2,3], further research is warranted to assess the BP-lowering effect of statins in addition to standard hypertensive treatment and to develop more effective multidisciplinary management of patients with both dyslipidaemia and hypertension.

ACKNOWLEDGMENTS

Writing support was provided by Stéphane Pintat (PhD) of Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca.

REFERENCES

1. De Bacquer D, De Backer G. The prevalence of concomitant hypertension and hypercholesterolaemia in the general population. *Int J Cardiol.* 2006; 110: 217–23.
2. Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: National Health and Nutrition Examination Surveys 1988-2010. *Circulation.* 2013; 128: 29–41.
3. Kabakci G, Koylan N, Ilerigelen B, Kozan O, Buyukozturk K. Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study. *Integr Blood Press Control.* 2008; 1: 5–13.
4. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med.* 1992; 152: 56–64.
5. Akesson A, Weismayer C, Newby PK, Wolk A. Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myocardial infarction in women. *Arch Intern Med.* 2007; 167: 2122–7.
6. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. *BMJ.* 2005; 331: 614.
7. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J.* 2012; 33: 1635–701.
8. Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. *Eur Heart J.* 2011; 32: 2143–52.
9. Hermans MP, Van Mieghem W, Vandenhoven G, Vissers E. Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS). *Acta Cardiologica.* 2009; 64: 177–85.

10. Schelleman H, Klungel OH, Kromhout D, de Boer A, Stricker BH, Verschuren WM. Prevalence and determinants of undertreatment of hypertension in the Netherlands. *J Hum Hypertens*. 2004; 18: 317–24.
11. Firmann M, Marques-Vidal P, Paccaud F, Mooser V, Rodondi N, Waeber G, et al. Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. *Eur J Cardiovasc Prev Rehabil*. 2010; 17: 682–7.
12. Guallar-Castillon P, Gil-Montero M, Leon-Munoz LM, Graciani A, Bayan-Bravo A, Taboada JM, et al. Magnitude and management of hypercholesterolemia in the adult population of Spain, 2008-2010: the ENRICA study. *Rev Esp Cardiol (Engl Ed)*. 2012; 65: 551–8.
13. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. *Hypertension*. 2004; 43: 10–7.
14. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013; 34: 2159–219.
15. Bonna KH, Thelle DS. Association between blood pressure and serum lipids in a population. The Tromsø Study. *Circulation*. 1991; 83: 1305–14.
16. Cicero AFG, D'Addato S, Veronesi M, Rosticci M, Santi F, Dormi A, et al. Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample: the Brisighella Heart Study. *J Hypertens*. 2012; 30: 492–6.
17. Borghi C, Cicero AF, Saragoni S, Buda S, Cristofori C, Lilli P, et al. Rate of control of LDL cholesterol and incident hypertension requiring antihypertensive treatment in hypercholesterolemic subjects in daily clinical practice. *Ann Med*. 2014; 46: 97–102.
18. Cicero A, Rosticci M, Baronio C, Morbini M, Parini A, Grandi E, et al. Serum LDL Cholesterol levels and new-onset of arterial hypertension: an 8-year follow-up. *Eur J Clin Invest*. 2014; 44: 926–32.
19. Briasoulis A, Agarwal V, Valachis A, Messerli FH. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. *J Clin Hypertens*. 2013; 15: 310–20.

20. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. *Hypertension*. 2007; 49: 792–8.
21. Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vohringer PA, Jeunemaitre X, et al. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. *Circulation*. 2015; 132: 1825–33.
22. Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. *Ann Med*. 2000; 32: 386–9.
23. Nickenig G, Wassmann S, Bohm M. Regulation of the angiotensin AT1 receptor by hypercholesterolaemia. *Diabetes Obes Metab*. 2000; 2: 223–8.
24. Murakami K, Uehara Y, Abe S, Inoue Y, Ideishi M, Saku K, et al. Positive correlation between chymase-like angiotensin II-forming activity in mononuclear cells and serum cholesterol level. *J Cardiol*. 2007; 50: 291–8.
25. Borghi C, Veronesi M, Cosentino E, Cicero AF, Kuria F, Dormi A, et al. Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. *J Hypertens*. 2007; 25: 2051–7.
26. Selby JV, Peng T, Karter AJ, Alexander M, Sidney S, Lian J, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. *Am J Manag Care*. 2004; 10: 163–70.
27. O'Meara JG, Kardia SL, Armon JJ, Brown CA, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. *Arch Intern Med*. 2004; 164: 1313–8.
28. Rodriguez-Artalejo F, Guallar E, Borghi C, Dallongeville J, De Backer G, Halcox JP, et al. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). *BMC Public Health*. 2010; 10: 382.
29. Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, et al. Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. *Eur J Cardiovasc Prev Rehabil*. 2011; 19: 541–50.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972; 18: 499–502.

31. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003; 289: 2560–72.
32. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA*. 2001; 285: 2486–97.
33. Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. *J Hypertens*. 2011; 29: 1641–8.
34. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002; 360: 1903–13.
35. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. *Arch Intern Med*. 1995; 155: 701–9.
36. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Scholkens BA, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. *Am J Physiol*. 1997; 272: H2701–H7.
37. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. *Circulation*. 1997; 95: 473–8.
38. Castejon AM, Zollner E, Tristano AG, Cubeddu LX. Upregulation of angiotensin II-AT1 receptors during statin withdrawal in vascular smooth muscle cells. *J Cardiovasc Pharmacol*. 2007; 50: 708–11.
39. Wassmann S, Nickenig G, Böhm M. Atorvastatin downregulates AT1-receptor gene expression and cell proliferation in vascular smooth muscle cells. *J Am Coll Cardio*. 1999; 33: 222A–3A.
40. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. *Arterioscler Thromb Vasc Biol*. 1998; 18: 1433–9.

41. Li D, Singh RM, Liu L, Chen H, Singh BM, Kazzaz N, et al. Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. *Cardiovasc Res.* 2003; 57: 238–43.
42. Uehara Y, Urata H, Sasaguri M, Ideishi M, Sakata N, Tashiro T, et al. Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. *Hypertension.* 2000; 35: 55–60.

TABLE 1. Socio-demographic and clinical characteristics of patients in EURIKA (N = 7641)

Characteristic	Overall (N = 7641)
Age (years)	63.2 (9.0)
Sex	
Men, <i>n</i> (%)	3696 (48.4)
Women, <i>n</i> (%)	3945 (51.6)
SBP (mmHg)	135.1 (16.6)
DBP (mmHg)	80.9 (9.9)
Normotensive, <i>n</i> (%)	701 (9.2)
Normal-to-high-normal BP, <i>n</i> (%)	1359 (17.9)
Hypertensive, <i>n</i> (%)	5559 (72.8)
Dyslipidaemia, <i>n</i> (%)	4948 (64.8)
Hypertension and dyslipidaemia, <i>n</i> (%)	3593 (47.0)
LDL-C (mmol/L)	3.2 (1.0)
HDL-C (mmol/L)	1.4 (0.4)
Non-HDL-C (mmol/L)	4.0 (1.1)
TC (mmol/L)	5.5 (1.1)
Apo-A1 (g/L)	1.5 (0.3)
Apo-B (g/L)	0.9 (0.2)

Data are mean (SD) unless otherwise stated. Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BP, blood pressure; DBP, diastolic blood pressure; EURIKA, European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol.

TABLE 2. Treatment characteristics in patients in EURIKA receiving antihypertensive treatment (*n* = 5239)

	Patients receiving antihypertensive treatment (<i>n</i> = 5239)
Number of antihypertensive drugs	
1	2041 (39.0)
2	1903 (36.3)
3	920 (17.6)
≥ 4	375 (7.1)
Type of antihypertensive drug	
Angiotensin II antagonists	2121 (40.5)
Anti-adrenergic agents	27 (0.5)
Beta-blocking agents	1787 (34.1)
Calcium channel blockers	1560 (29.8)
Diuretics	2397 (45.8)
ACE inhibitors	1912 (36.5)
Alpha-adrenergic antagonist	166 (3.2)
Other antihypertensive agent	223 (4.3)

Data are n (%). ACE, angiotensin-converting enzyme; EURIKA, European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice.

TABLE 3. Relationship between blood pressure and serum lipid profile for patients in EURIKA

	Model A ^a		Model B ^b
	Regression coefficient (95% CI)	<i>P</i> value ^c	Regression coefficient (95% CI)
Association with SBP			
LDL-C	0.93 (0.54 to 1.31) ^d	< 0.0001	0.95 (0.56 to 1.34) ^d
HDL-C	-0.21 (-1.20 to 0.78) ^d	0.6786	0.40 (-0.57 to 1.38) ^d
Non-HDL-C	1.07 (0.73 to 1.40) ^d	< 0.0001	1.06 (0.72 to 1.39) ^d
Total cholesterol	1.02 (0.69 to 1.35) ^d	< 0.0001	1.08 (0.75 to 1.41) ^d
Apo-A1	1.66 (0.23 to 3.10) ^e	0.0233	2.45 (1.04 to 3.85) ^e
Apo-B	4.94 (3.43 to 6.46) ^e	< 0.0001	4.85 (3.35 to 6.35) ^e
Association with DBP			
LDL-C	0.96 (0.73 to 1.19) ^d	< 0.0001	0.85 (0.61 to 1.09) ^d
HDL-C	-0.50 (-1.09 to 0.10) ^d	0.1012	-0.42 (-1.01 to 0.17) ^d

Non-HDL-C	0.95 (0.75 to 1.15) ^d	<0.0001	0.88 (0.67 to 1.08) ^d
Total cholesterol	0.87 (0.67 to 1.07) ^d	<0.0001	0.81 (0.61 to 1.01) ^d
Apo-A1	0.34 (-0.52 to 1.20) ^e	0.4371	0.60 (-0.25 to 1.45) ^e
Apo-B	4.33 (3.42 to 5.23) ^e	<0.0001	4.04 (3.14 to 4.95) ^e

Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; ESCAPE, European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

^aLinear regressions adjusted for sex, age and BMI.

^bLinear regressions adjusted for sex, age, BMI, statin use, antihypertensive treatment (yes/no), number of cardiovascular risk factors (0/1/2/3 among dyslipidaemia, smoking and diabetes), physical activity and country.

^cSignificant *P* values (<0.05) in bold.

^dmmHg/mmol/L.

^emmHg/g/L.

TABLE 4. Relationship between blood pressure and serum lipid profile for patients in EURIKA treated

	Without statin (<i>n</i> = 4601)		With statin (<i>n</i> = 3000)	
	SBP	DBP	SBP	DBP
LDL-C	1.01 (0.49 to 1.53) ^{a,b}	0.72 (0.41 to 1.04) ^{a,b}	0.94 (0.35 to 1.52) ^{a,b}	1.05 (0.46 to 1.64) ^{a,b}
HDL-C	0.09 (-1.16 to 1.34) ^{a,b}	-0.61(-1.37 to 0.14) ^{a,b}	1.10 (-0.43 to 2.63) ^{a,b}	0.40 (-0.84 to 1.04) ^{a,b}
Non-HDL-C	1.08 (0.63 to 1.53) ^{a,b}	0.79 (0.53 to 1.07) ^{a,b}	1.06 (0.57 to 1.55) ^{a,b}	0.93 (0.44 to 1.42) ^{a,b}
Total cholesterol	1.08 (0.63 to 1.53) ^{a,b}	0.71 (0.44 to 0.98) ^{a,b}	1.13 (0.65 to 1.62) ^{a,b}	0.94 (0.45 to 1.43) ^{a,b}
Apo-A1	2.18 (0.35 to 4.01) ^{a,c}	0.35 (-0.76 to 1.45) ^{a,c}	2.84 (0.65 to 5.02) ^{a,c}	1.35 (0.16 to 2.54) ^{a,c}
Apo-B	4.59 (2.59 to 6.59) ^{a,c}	3.46 (2.26 to 4.67) ^{a,c}	5.33 (3.07 to 7.59) ^{a,c}	4.56 (2.80 to 6.32) ^{a,c}

Numbers in bold are statistically significant ($P < 0.05$). Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B.

SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

^aRegression coefficient (95% confidence intervals) analysis adjusted for age, sex, BMI, antihypertensive treatment, and country.

^bmmHg/mmol/L.

^cmmHg/g/L.

TABLE 5. Relationship between pulse pressure and serum lipid profile for patients in EURIKA treated

	Overall (<i>N</i> = 7641)	Without statin (<i>n</i> = 4601)
LDL-C	0.09 (−0.22 to 0.41) ^{a,c}	0.28 (−0.13 to 0.69) ^{b,c}
HDL-C	0.83 (0.05 to 1.61) ^{a,c}	0.70 (−0.28 to 1.69) ^{b,c}
Non-HDL-C	0.18 (−0.09 to 0.45) ^{a,c}	0.28 (−0.08 to 0.64) ^{b,c}
Total cholesterol	0.27 (0.01 to 0.54) ^{a,c}	0.37 (0.01 to 0.72) ^{b,c}
Apo-A1	0.57 (0.73 to 2.98) ^{a,d}	1.83 (0.38 to 3.27) ^{b,d}
Apo-B	0.78 (−0.42 to 1.98) ^{a,d}	1.09 (−0.49 to 2.67) ^{b,d}

Numbers in bold are statistically significant ($P < 0.05$). Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PP, pulse pressure. ^aRegression coefficient (95% confidence intervals) analysis adjusted for sex, age, BMI, statin use, and

number of cardiovascular risk factors (0/1/2/3 among dyslipidaemia, smoking and diabetes), physical activity

^bRegression coefficient (95% confidence intervals) analysis adjusted for age, sex, BMI, antihypertensive treatment, and country.

^cmmHg/mmol/L.

^dmmHg/g/L.

SUPPLEMENTARY TABLE 1. Socio-demographic and clinical characteristics of patients in EURIKA

	Aus (n = 624)	Bel (n = 638)	Fra (n = 593)	Ger (n = 678)	Gre (n = 620)	Nor (n = 611)	Rus (n = 604)	Spa (n = 642)	Sw (n = 611)
Age, mean (SD)	61.9 (8.6)	64.6 (8.9)	64.1 (8.8)	65.3 (8.8)	65.3 (8.9)	62.9 (8.8)	58.3 (7.3)	63.1 (9.0)	64.9 (8.9)
Sex, n (%)									
Men	297 (47.6)	312 (48.9)	325 (54.8)	333 (49.1)	285 (46.0)	298 (48.8)	192 (31.8)	330 (51.4)	315 (51.6)
Women	327 (52.4)	326 (51.1)	268 (45.2)	345 (50.9)	335 (54.0)	313 (51.2)	412 (68.2)	312 (48.6)	313 (50.4)
Hypertension, ^a n (%)	447 (61.4)	448 (70.2)	434 (73.2)	549 (81.0)	413 (66.6)	426 (69.7)	486 (80.5)	435 (67.8)	516 (84.8)
Dyslipidaemia, ^b n (%)	359 (57.5)	427 (66.9)	361 (60.9)	412 (60.8)	457 (73.7)	401 (65.6)	423 (70.0)	436 (67.9)	397 (64.9)
Hypertension and dyslipidaemia, n (%)	269 (43.1)	292 (45.8)	262 (44.2)	334 (49.3)	301 (48.5)	275 (45.0)	353 (58.4)	290 (45.2)	328 (53.2)

Aus, Australia; Bel, Belgium; DBP, diastolic blood pressure; EURIKA, European Study on Cardiovascular Risk in Usual Daily Practice; Fra, France; Ger, Germany; Gre, Greece; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; Nor, Norway; Rus, Russia; SBP, systolic blood pressure; Spa, Spain; Swe, Sweden; Swi, Switzerland; Tur, Turkey

Usual Daily Practice; Fra, France; Ger, Germany; Gre, Greece; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; Nor, Norway; Rus, Russia; SBP, systolic blood pressure; Spa, Spain; Swe, Sweden; Swi, Switzerland; Tur, Turkey

Norway; Rus, Russia; SBP, systolic blood pressure; Spa, Spain; Swe, Sweden; Swi, Switzerland; Tur, Turkey

^aSBP \geq 140 mmHg and/or DBP \geq 90 mmHg or being treated with one or more antihypertensive drugs.

^bLDL-C concentration \geq 4.9 mmol/L (190 mg/dL), a serum HDL-C concentration $<$ 1.0 mmol/L (40 mg/dL) for men or $<$ 0.8 mmol/L (30 mg/dL) for women, a non-HDL-C concentration \geq 5.2 mmol/L (200 mg/dL) for men or \geq 4.9 mmol/L (190 mg/dL) for women, or being treated with one or more lipid-lowering medication

FIGURE LEGENDS

FIGURE 1 Scatterplots of patients' systolic blood pressure and lipid levels, according to statin treatment. Dotted and solid lines represent regression lines for non-users and users of statins, respectively. Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

FIGURE 2 Scatterplots of patients' diastolic blood pressure and lipid levels, according to statin treatment. Dotted and solid lines represent regression lines for non-users and users of statins, respectively. Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

FIGURE 3 Scatterplots of patients' pulse pressure and lipid levels, according to statin treatment. Dotted and solid lines represent regression lines for non-users and users of statins, respectively. Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Figure 1




Figure 2




Figure 3

